Cardiometabolic Risk in Polycystic Ovary Syndrome
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome is a common endocrine disorder in reproductive-aged women and is associated with an increased risk of metabolic abnormalities, including obesity, impaired glucose tolerance, diabetes, dyslipidemia, metabolic syndrome, venous thromboembolism, and subclinical atherosclerosis. Clinicians and patients alike need to be aware of these increased risks as well as new international guidelines that recommend frequent screening and active management of metabolic abnormalities. Given that the data on risk of cardiovascular events, such as myocardial infarction and stroke, in women with PCOS is mixed, future large-scale, longitudinal studies are needed to clarify these potential risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989
Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M., & Sitzer, M. (2007) · Circulation · doi:10.1161/circulationaha.106.628875 · Cited by 2,977
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Self-citationBozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526
Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.003 · Cited by 1,358
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325 · cited 1×
“International guidelines recommend that women with PCOS should be monitored for weight changes every 6 months to 12 months (Table 1).(13,14) Given the association between negative body image and low self-esteem, it is important for providers to be tactful in discussing the risk of weight gain and obesity and participa…”
BackgroundSelf-citationLim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms030 · Cited by 939
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Edelstein, S. L., Knowler, W. C., Bain, R. P., Andres, R., Barrett-Connor, E. L., Dowse, G. K., Haffner, S. M., Pettitt, D. J., Sorkin, J. D., Muller, D. C., et al. (1997) · Diabetes · doi:10.2337/diabetes.46.4.701 · Cited by 641
Cooney, L. G., Lee, I., Sammel, M. D., & Dokras, A. (2017) · Human Reproduction · doi:10.1093/humrep/dex044 · Cited by 631
Self-citationMenstrual cycle irregularity and risk for future cardiovascular disease
Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer, F. E., & Manson, J. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8471 · Cited by 528
Talbott, E. O., Guzick, D. S., Sutton-Tyrrell, K., McHugh-Pemu, K. P., Zborowski, J. V., Remsberg, K. E., & Kuller, L. H. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.11.2414 · Cited by 511
Lipid Levels in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis
Wild, R. A., Rizzo, M., Clifton, S., & Carmina, E. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.12.027 · Cited by 477 · cited 1×
“In studies that matched on BMI, the association between PCOS and elevated LDL-C and non–HDL-C persisted.(32) The HA phenotype is associated with a higher risk of dyslipidemia with low HDL-C in women with HAPCOS.”
BackgroundObesity and androgens: facts and perspectives
Pasquali, R. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.10.054 · Cited by 469
Day, F. R., Hinds, D. A., Tung, J. Y., Stolk, L., Styrkarsdottir, U., Saxena, R., Bjonnes, A., Broer, L., Dunger, D. B., Halldorsson, B. V., et al. (2015) · Nature Communications · doi:10.1038/ncomms9464 · Cited by 459 · cited 1×
“Approximately 60% of women with PCOS are obese,(3) and this risk appears to have a genetic predisposition.(4) Not only does obesity increase the risk of other metabolic complications associated with PCOS, such as dyslipidemia, type 2 diabetes mellitus (DM), HTN, and pregnancy complications, such as preeclampsia and ge…”
BackgroundGibson-Helm, M., Teede, H., Dunaif, A., & Dokras, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2963 · Cited by 428 · cited 1×
“Not only does obesity increase the risk of other metabolic complications associated with PCOS, such as dyslipidemia, type 2 diabetes mellitus (DM), HTN, and pregnancy complications, such as preeclampsia and gestational diabetes, but also it is one of the most common characteristics of PCOS that is cited by patients as…”
BackgroundSelf-citationImpact of Obesity on the Risk for Polycystic Ovary Syndrome
Yildiz, B. O., Knochenhauer, E. S., & Azziz, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1834 · Cited by 401 · cited 6×
“The guidelines also suggest considering the use of metformin in women with PCOS with BMI greater than or equal to 25 kg/m2 without IGT/DM,14 Metformin has been shown to decrease progression from IGT to DM in the general population30 and to decrease BMI in women with PCOS.31”
BackgroundInfluentialThe Potential Implications of a PCOS Diagnosis on a Woman's Long-Term Health Using Data Linkage
Hart, R., & Doherty, D. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3886 · Cited by 391 · cited 4×
“Population-based studies also have shown higher rates of DM in women with PCOS, some of which also adjusted for BMI.(22,23) A large cross-sectional study found higher rates of insulin resistance in the HA PCOS phenotypes but no difference in rates of hyperglycemia in PCOS phenotypes.”
BackgroundResultInfluentialKakoly, N. S., Khomami, M. B., Joham, A. E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., Ranasinha, S., Teede, H. J., & Moran, L. J. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy007 · Cited by 384
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv025 · Cited by 334
Lim, S. S., Kakoly, N. S., Tan, J. W. J., Fitzgerald, G., Bahri Khomami, M., Joham, A. E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., et al. (2019) · Obesity Reviews · doi:10.1111/obr.12762 · Cited by 316
Beyond fertility: polycystic ovary syndrome and long-term health
Cooney, L. G., & Dokras, A. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.08.021 · Cited by 270
Self-citationLegro, R. S., Dodson, W. C., Kris-Etherton, P. M., Kunselman, A. R., Stetter, C. M., Williams, N. I., Gnatuk, C. L., Estes, S. J., Fleming, J., Allison, K. C., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2778 · Cited by 242 · cited 1×
“The prevalence of MetS increases with use of OCPs in overweight/obese women with PCOS and can bemitigated by lifestyle modifications.(43) In summary, the risk of MetS clearly is higher in adolescent and reproductive-aged women with PCOS in several regions of the world.”
BackgroundSelf-citationSchmidt, J., Landin-Wilhelmsen, K., Brännström, M., & Dahlgren, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1677 · Cited by 241 · cited 6×
“The guidelines also suggest considering the use of metformin in women with PCOS with BMI greater than or equal to 25 kg/m2 without IGT/DM,14 Metformin has been shown to decrease progression from IGT to DM in the general population30 and to decrease BMI in women with PCOS.31”
BackgroundInfluentialDaan, N. M. P., Louwers, Y. V., Koster, M. P. H., Eijkemans, M. J. C., de Rijke, Y. B., Lentjes, E. W. G., Fauser, B. C. J. M., & Laven, J. S. E. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.08.001 · Cited by 217 · cited 4×
“The HA phenotype is associated with a higher risk of dyslipidemia with low HDL-C in women with HAPCOS.(11) Among women with PCOS, non-Hispanic black women may have a lower prevalence of dyslipidemia compared with both Hispanics and non-Hispanic whites.”
BackgroundResultInfluentialCardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome
Glintborg, D., Rubin, K. H., Nybo, M., Abrahamsen, B., & Andersen, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0680-5 · Cited by 200 · cited 8×
“In the absence of definitive data from other sources, however, population-based studies can be helpful in evaluating the risk of CV events because they allow for large sample sizes, long follow-up times, and, in some cases, adjusting for confounders, such as BMI.”
BackgroundInfluentialRubin, K. H., Glintborg, D., Nybo, M., Abrahamsen, B., & Andersen, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01354 · Cited by 195
Ollila, M.-M. E., Piltonen, T., Puukka, K., Ruokonen, A., Järvelin, M.-R., Tapanainen, J. S., Franks, S., & Morin-Papunen, L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3543 · Cited by 182 · cited 6×
“The guidelines also suggest considering the use of metformin in women with PCOS with BMI greater than or equal to 25 kg/m2 without IGT/DM,14 Metformin has been shown to decrease progression from IGT to DM in the general population30 and to decrease BMI in women with PCOS.31”
BackgroundInfluentialMeyer, M. L., Malek, A. M., Wild, R. A., Korytkowski, M. T., & Talbott, E. O. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr046 · Cited by 175 · cited 1×
“0001; meta-analysis of 19 studies).(51) In the general population, for every 0.”
MethodThe Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome
Kakoly, N. S., Earnest, A., Teede, H. J., Moran, L. J., & Joham, A. E. (2019) · Diabetes Care · doi:10.2337/dc18-1738 · Cited by 174 · cited 8×
“Although cross-sectional studies do not show an increased risk of DM independent of BMI, multiple larger population-based and longitudinal studies have demonstrated an increased risk of DM even after adjusting for BMI.(19,22,23,27) Future studies should focus on evaluation of the risk of IGT/DM in adolescents.”
BackgroundInfluentialPolycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis.
Zhao, L., Zhu, Z., Lou, H., Zhu, G., Huang, W., Zhang, S., & Liu, F. (2016) · Oncotarget · doi:10.18632/oncotarget.9553 · Cited by 174
Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype
Engmann, L., Jin, S., Sun, F., Legro, R. S., Polotsky, A. J., Hansen, K. R., Coutifaris, C., Diamond, M. P., Eisenberg, E., Zhang, H., et al. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.01.003 · Cited by 144 · cited 6×
“US studies show that Hispanic and black women have higher degrees of insulin resistance compared with non-Hispanic whites.(16,17) The increased prevalence of IGT was noted in body mass index (BMI)-matched (2.”
BackgroundInfluentialIncreased risk of disordered eating in polycystic ovary syndrome
Lee, I., Cooney, L. G., Saini, S., Smith, M. E., Sammel, M. D., Allison, K. C., & Dokras, A. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.014 · Cited by 127
Self-citationZhu, S., Zhang, B., Jiang, X., Li, Z., Zhao, S., Cui, L., & Chen, Z.-J. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.09.013 · Cited by 109
Yang, R., Yang, S., Li, R., Liu, P., Qiao, J., & Zhang, Y. (2016) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-016-0203-8 · Cited by 106
Kazemi Jaliseh, H., Ramezani Tehrani, F., Behboudi-Gandevani, S., Hosseinpanah, F., Khalili, D., Cheraghi, L., & Azizi, F. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.09.004 · Cited by 80
Epidemiology and Comorbidities of Polycystic Ovary Syndrome in an Indigent Population
Sirmans, S. M., Parish, R. C., Blake, S., & Wang, X. (2014) · Journal of Investigative Medicine · doi:10.1097/01.jim.0000446834.90599.5d · Cited by 79 · cited 1×
“Two studies did not show increased rates of VD events; however, the mean ages were less than 30 years.(23,73) There is 1 meta-analysis evaluating just population studies, which found a higher odds of CV events and mortality due to CV events in women with PCOS (OR 1.”
BackgroundForslund, M., Landin-Wilhelmsen, K., Trimpou, P., Schmidt, J., Brännström, M., & Dahlgren, E. (2020) · Human Reproduction Open · doi:10.1093/hropen/hoz042 · Cited by 66
Zhou, Y., Wang, X., Jiang, Y., Ma, H., Chen, L., Lai, C., Peng, C., He, C., & Sun, C. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1347779 · Cited by 64
Cited by
Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00511-3 · Cited by 495
“…of cardiometabolic risk factors, including excess weight, impaired glucose tolerance, T2DM, dyslipidaemia, hypertension and metabolic syndrome 8–11 , are consistently higher in women with PCOS, likely contributing to the increased odds for cardiovascular disease, including ischaemic heart…”
InfluentialSelf-citationChen, J., Huang, C., Zhang, T., Gong, W., Deng, X., Liu, H., Liu, J., & Guo, Y. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00863-5 · Cited by 18
Metadata
- Authors
- Cooney, L. G., & Dokras, A.
- Venue
- Endocrinology and Metabolism Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 50
- Issue
- 1
- Pages
- 83-95
- ISSN
- 0889-8529 (ISSN-L)
- OpenAlex
- W3120157680
- Cited by
- 44
- References
- 42
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.